Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to < 24 Months of Age at Treatment Initiation

Condition:   Cystic Fibrosis Intervention:   Drug: LUM/IVA Sponsor:   Vertex Pharmaceuticals Incorporated Not yet recruiting

Source: ClinicalTrials.gov - January 20, 2020 Category: Research Source Type: clinical trials